NYSE:KDMNKadmon Stock Price, Forecast & News

Kadmon's stock was trading at $3.48 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, KDMN stock has increased by 27.6% and is now trading at $4.44. View which stocks have been most impacted by Coronavirus.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kadmon in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Kadmon.

Kadmon is scheduled to release its next quarterly earnings announcement on Monday, August 3rd 2020. View our earnings forecast for Kadmon.

Kadmon Holdings Inc (NYSE:KDMN) announced its quarterly earnings data on Thursday, May, 7th. The company reported ($0.19) EPS for the quarter, missing analysts' consensus estimates of ($0.14) by $0.05. The business had revenue of $6.74 million for the quarter, compared to analyst estimates of $0.38 million. Kadmon had a negative return on equity of 142.79% and a negative net margin of 813.33%. View Kadmon's earnings history.

5 brokerages have issued twelve-month target prices for Kadmon's shares. Their forecasts range from $7.00 to $25.00. On average, they expect Kadmon's stock price to reach $12.00 in the next year. This suggests a possible upside of 170.3% from the stock's current price. View analysts' price targets for Kadmon.

Media headlines about KDMN stock have been trending very positive this week, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Kadmon earned a coverage optimism score of 3.5 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View the latest news aboutKadmon.

Some companies that are related to Kadmon include Amarin (AMRN), Taro Pharmaceutical Industries (TARO), Alkermes (ALKS), Apellis Pharmaceuticals (APLS), Turning Point Therapeutics (TPTX), Insmed (INSM), Karuna Therapeutics (KRTX), Intercept Pharmaceuticals (ICPT), Ra Pharmaceuticals (RARX), Prestige Consumer Healthcare (PBH), Principia Biopharma (PRNB), TG Therapeutics (TGTX), IGM Biosciences (IGMS), Eidos Therapeutics (EIDX) and Passage Bio (ZNTL). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Kadmon investors own include Iovance Biotherapeutics (IOVA), Applied Materials (AMAT), Biocept (BIOC), Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Viking Therapeutics (VKTX), Bristol-Myers Squibb (BMY), Crispr Therapeutics (CRSP), SCYNEXIS (SCYX) and Global Blood Therapeutics (GBT).

(KDMN) raised $101 million in an initial public offering on Wednesday, July 27th 2016. The company issued 5,600,000 shares at $16.00-$20.00 per share. Citigroup and Jefferies served as the underwriters for the IPO and JMP Securities and H.C. Wainwright & Co. were co-managers.

Kadmon trades on the New York Stock Exchange (NYSE) under the ticker symbol "KDMN."

Kadmon's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Perceptive Advisors LLC (9.82%), Vivo Capital LLC (7.84%), BlackRock Inc. (7.53%), State Street Corp (2.33%), Geode Capital Management LLC (1.41%) and Invesco Ltd. (1.12%). Company insiders that own Kadmon stock include Cynthia Schwalm, Harlan Waksal and Perceptive Advisors Llc. View institutional ownership trends for Kadmon.

KDMN stock was sold by a variety of institutional investors in the last quarter, including Sofinnova Investments Inc., Invesco Ltd., Nuveen Asset Management LLC, Ghost Tree Capital LLC, Two Sigma Investments LP, Soleus Capital Management L.P., Telemetry Investments L.L.C., and Acadian Asset Management LLC. View insider buying and selling activity for Kadmon.

KDMN stock was bought by a variety of institutional investors in the last quarter, including Vivo Capital LLC, BlackRock Inc., Ikarian Capital LLC, Morgan Stanley, Morgan Stanley, Perceptive Advisors LLC, Healthcare of Ontario Pension Plan Trust Fund, and Two Sigma Advisers LP. Company insiders that have bought Kadmon stock in the last two years include Cynthia Schwalm, Harlan Waksal, and Perceptive Advisors Llc. View insider buying and selling activity for Kadmon.

Shares of KDMN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of KDMN stock can currently be purchased for approximately $4.44.

Kadmon has a market capitalization of $710.52 million and generates $5.09 million in revenue each year. The company earns $-61,370,000.00 in net income (profit) each year or ($0.74) on an earnings per share basis. Kadmon employs 116 workers across the globe.

The official website for Kadmon is www.kadmon.com.

Kadmon's mailing address is 450 East 29th Street, New York NY, 10016. The company can be reached via phone at 833-900-5366 or via email at [email protected]